SAO PAULO • A coronavirus vaccine developed by China's Sinovac Biotech was 78 per cent effective in a late-stage Brazilian trial, with no severe Covid-19 cases, researchers said, although a lack of data details stirred calls for more transparency.
The trial results, closely watched by developing countries counting on
"it's something else to get the data and analyse it, which is what Anvisa will do"
